We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put s... AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Show more
First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III...
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading...
ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire ROCKVILLE, Md., April 25, 2024 ROCKVILLE...
U.S. index futures fell in pre-market trading on Thursday, particularly technology stocks, which saw a significant depreciation after Meta Platforms (NASDAQ:META) announced disheartening...
Southwest Airlines (NYSE:LUV) – Southwest Airlines’ shares fell 9.6% in pre-market trading after reporting a larger first-quarter loss compared to the previous year and warned of...
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca: Revenue and EPS summary Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15...
Longest survival follow-up ever reported for immunotherapy treatment in this setting Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in...
Paramount Global (NASDAQ:PARA) – Some investors in Paramount Global are concerned about a potential merger with Skydance Media and are calling for a fair approach. Skydance, known for hits...
Meta Platforms (NASDAQ:META) – Meta Platforms disclosed details on Wednesday about its upcoming generation of internal AI accelerator chip, named Artemis, aiming to lessen its dependence on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions